Sanofi aims to double vaccine sales by 2030, citing RSV and flu market expansion as key drivers

While Sanofi hasn’t been at the forefront of global COVID-19 vaccination efforts, the company still has big growth expectations in the vaccines field. Already the world’s top flu shot player, Sanofi sees mRNA, pneumococcal vaccines and respiratory syncytial virus (RSV) as three areas of opportunity going forward.